Results 121 to 130 of about 454 (177)

Efficacy and safety of natural killer cells injection combined with XELOX chemotherapy in postoperative patients with stage III colorectal cancer in China: a prospective randomised controlled clinical trial study protocol. [PDF]

BMJ Open
Geng S, Yu X, Yu S.
europepmc   +1 more source

Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy. [PDF]

Medicine (Baltimore), 2020
Mao J, Du P, Yang HT, Hu H, Wang SY, Wu X, Cheng ZB.   +6 more
europepmc   +1 more source

Histidine Promotes the Glucose Synthesis through Activation of the Gluconeogenic Pathway in Bovine Hepatocytes. [PDF]

Animals (Basel), 2021
Yang T, Cheng Z, Jiang M, Ma X, Datsomor O, Zhao G, Zhan K.   +6 more
europepmc   +1 more source

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients. [PDF]

Medicine (Baltimore), 2020
Geng R, Wang G, Qiu L, Liu B, Yang F, Zhang J, Miao Y.   +6 more
europepmc   +1 more source

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. [PDF]

Signal Transduct Target Ther
Qiu MZ, Bai Y, Wang J, Gu K, Yang M, He Y, Yi C, Jin Y, Liu B, Wang F, Chen YK, Dai W, Jiang Y, Huang C, Xu RH, Luo HY.   +15 more
europepmc   +1 more source

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110). [PDF]

ESMO Open
Boukovala M, Modest DP, Ricard I, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Heinrich K, Neumann J, Jung A, Held S, Stintzing S, Heinemann V, Michl M.   +21 more
europepmc   +1 more source

Some properties of oxaloacetate-synthesizing enzyme [PDF]

Biochemical Journal, 1959
openaire   +2 more sources

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial. [PDF]

ESMO Open
Scanlon E, Lavery A, Albraikat M, Stevenson L, Kennedy C, Byrne R, Walker A, Mullan-Young B, McManus DT, Virdee PS, Elhussein L, Turbitt J, Collinson D, Miedzybrodzka Z, Van Schaeybroeck S, McQuaid S, James JA, Craig SG, Blayney JK, Petty RD, Harkin DP, Kennedy RD, Eatock MM, Middleton MR, Thomas A, Turkington RC.   +25 more
europepmc   +1 more source

Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.

JAMA Oncol
Peng Z, Zhang X, Liang H, Zheng Z, Wang Z, Liu H, Hu J, Sun Y, Zhang Y, Yan H, Tong L, Xu J, Ji J, Shen L.   +13 more
europepmc   +1 more source

Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. [PDF]

J Clin Oncol
Jia R, Shan T, Zheng A, Zhang Y, Lu P, Zhang G, Wang F, Xu Z, Zheng G, Tang D, Zhang W, Li W, Li R, Guo Y, Liu L, Luo X, Zheng Y, Chang Z, Wang Q, Wang X, Yuan X, Kong G, Li S, Yang R, Zhou D, Ren J, Yin W, Li J, Zhang J, Wang Z, Sheng M, Xu B, Li L, Liu X, Lu Z, Wan L, Zhou F, Gao S.   +37 more
europepmc   +1 more source